MedTrace Logo

A Study of Aspirin and Simvastatin in Pulmonary Arterial Hypertension

NCT00384865 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2017-07-21

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether aspirin and simvastatin are safe and effective for the treatment of pulmonary arterial hypertension (PAH).

Conditions

  • Hypertension, Pulmonary

Interventions

DRUG

Simvastatin

Simvastatin 40 mg, taken orally, once a day for 6 months

DRUG

Aspirin

Aspirin 81 mg, taken orally, once a day for 6 months

DRUG

Placebo

Placebo, taken orally, once a day for 6 months

Sponsors & Collaborators

Principal Investigators

  • Steven M Kawut, MD, MS · University of Pennsylvania

  • David J Lederer, MD, MS · Columbia University

  • Reda E Girgis, MB, BCh · Johns Hopkins University

  • Kari E Roberts, MD · Tufts University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-09-30
Primary Completion
2009-10-31
Completion
2009-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00384865 on ClinicalTrials.gov